Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M, EMPEROR-Preserved Trial Committees and Investigators

Open source

DOI: 10.1002/ejhf.1596
Published: 2019 Oct
Container: European journal of heart failure
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ejhf.1596,
  title = {Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.},
  author = {Anker SD and Butler J and Filippatos GS and Jamal W and Salsali A and Schnee J and Kimura K and Zeller C and George J and Brueckmann M and Zannad F and Packer M and EMPEROR-Preserved Trial Committees and Investigators},
  year = {2019},
  journal = {European journal of heart failure},
  doi = {10.1002/ejhf.1596},
  url = {https://doi.org/10.1002/ejhf.1596}
}

RIS

TY  - JOUR
TI  - Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
AU  - Anker SD
AU  - Butler J
AU  - Filippatos GS
AU  - Jamal W
AU  - Salsali A
AU  - Schnee J
AU  - Kimura K
AU  - Zeller C
AU  - George J
AU  - Brueckmann M
AU  - Zannad F
AU  - Packer M
AU  - EMPEROR-Preserved Trial Committees and Investigators
PY  - 2019
JO  - European journal of heart failure
DO  - 10.1002/ejhf.1596
UR  - https://doi.org/10.1002/ejhf.1596
ER  -

APA

SD, A., J, B., GS, F., W, J., A, S., J, S., K, K., C, Z., J, G., M, B., F, Z., M, P., & Investigators, E. T. C. A. (2019). Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.. European journal of heart failure. https://doi.org/10.1002/ejhf.1596

Source records

pubmed · retrieved 2026-09-27T10:57:02.676Z